Development of Escherichia coli strands resistant to quinolones in stools of patients with liver cirrhosis submitted to selective bowel decontamination;Aparición de cepas de Escherichia coli resistentes a quinolonas en las heces de pacientes cirróticos sometidos a descontaminación intestinal selectiva

Medicina Clinica

Volumn 113, Issue 7, 1999, Pages 241-245

  Aparicio, José Ramón ^b   Such Ronda, José ^a   Gutiérrez, Ana ^b   Pérez Mateo, Miguel ^b   Plaza, Joaquín ^b   Arroyo, Ángeles ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b NONE

Author keywords

Bowel decontamination; Cirrhosis; Escherichia coli; Resistance to quinolones

Indexed keywords

NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL PERITONITIS; CONTROLLED STUDY; ESCHERICHIA COLI; FECES MICROFLORA; HUMAN; INFECTION RISK; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; RISK FACTOR; DRUG EFFECT; ENTEROBACTER INFECTION; FECES; FEMALE; GASTROINTESTINAL DISEASE; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; PERITONITIS; PROSPECTIVE STUDY;

AGED; ANTI-INFECTIVE AGENTS; ANTIBIOTIC PROPHYLAXIS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FECES; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NORFLOXACIN; PERITONITIS; PROSPECTIVE STUDIES; RISK FACTORS; STATISTICS, NONPARAMETRIC;

EID: 0033546814     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 1993; 18: 353-358
2. Palazón JM, García A, Gómez A. Infecciones hospitalarias en pacientes con cirrosis hepática. Gastroenterol Hepatol 1984; 7: 120-122.
3. Rimola A. Infecciones bacterianas en la cirrosis hepática. MTA-Medicina Interna 1987; 5: 161-224.
4. Felisart J, Rimola A, Arroyo V, Pérez Ayuso RM, Quintero E, Ginès P et al. Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatology 1985; 5: 457-462.
5. Guarner C, Runyon BA. Spontaneous bacterial peritonitis: pathogenesis, diagnosis and management. Gastroenterologist 1995; 3: 311-328.
6. Runyon BA. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology 1986; 91: 1.343-1.346.
7. 3 in cirrhotic ascites predisposes to spontaneous bacterial peritonitis. J Hepatol 1988; 6: 80-84.
8. Rimola A, Bory F, Teres J, Pérez Ayuso RM, Arroyo V, Rodés J. Oral, nonabsorbable antibiotics prevent infection in cirrhotics with gastrointestinal hemorrhage. Hepatology 1985; 5: 463-467.
9. Soriano G, Guarner C, Tomás A, Villanueva C, Torras X, González D et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology 1992; 103: 1.267-1.272.
10. Ginès P, Rimola A, Planas R, Vargas V, Marco F, Almela M et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990; 12: 716-724.
11. Soriano G, Guarner C, Teixidó M, Such J, Barrios J, Enriquez J et al. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology 1991; 100: 477-481.
12. Bernard B, Grange JD, Nguyen E, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis (AbP) for the prevention of bacterial infections in cirrhotic patients with ascites: a meta-analysis [resumen]. Hepatology 1996; 24: 444.
13. Grange JD, Bernard B, Nguyen E, Opolon P, Poynard T. Antibiotic prophylaxis (AbP) for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding (GB): a meta-analysis [resumen]. Hepatology 1996; 24: 444.
14. Inadomi J, Sonnenberg A. Cost-analysis of prophylactic antibiotics in spontaneous bacterial peritonitis. Gastroenterology 1997; 113: 1.289-1.294.
15. Carratalá J, Fernández-Sevilla A, Tubau F, Domínguez MA, Gudiol F. Emergence of fluorquinolone-resistant Escherichia coli fecal flora of cancer patients receiving norfloxacin prophylaxis. Antimicrob Agents Chemother 1996; 40: 503-505.
16. Dupeyron C, Mangeney N, Sedrati L, Campillo B, Fouet P, Leluan G. Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. Antimicrob Agents Chemother 1994; 38: 340-344.
17. Novella M, Solá R, Soriano G, Andreu M, Gana J, Ortiz J et al. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. Hepatology 1997; 25: 532-536,
18. Castellote J, Xiol J, Rota Roca R, Fernández Esparrach G. Spontaneous bacterial peritonitis and empyema by Escherichia coli resistant to norfloxacine in a patient on selective intestinal decontamination with norfloxacine. J Hepatol 1994; 20: 436.
19. Cometta A, Calandra T, Bille J, Glauser MP. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 1994; 330: 1.240-1.241.
20. Rolachon A, Cordier L, Bacq Y, Nousbaum JB, Franza A, Paris JC et al. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Hepatology 1995; 22: 1.171-1.174.
21. Tomás A, Soriano G, Guarner C, Portorreal R, Novella MT, Vilardell F. Hospital-acquired bacterial infections in patients with cirrhosis undergoing selective intestinal decontamination [carta]. J Hepatol 1993; 18: 262-263.
22. Llovet JM, Rodríguez Iglesias P, Moitinho E, Planas R, Bataller R, Navasa M et al. Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination. A retrospective study of 229 spontaneous bacterial peritonitis episodes. J Hepatol 1997; 26: 88-95.
23. a ed.). Virginia: Antimicrobial therapy, 1997.
24. Guarner C, Runyon BA, Young S, Heck M, Sheikh MY. Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J Hepatol 1997; 26: 1.372-1.378.